51黑料吃瓜在线观看,51黑料官网|51黑料捷克街头搭讪_51黑料入口最新视频

心血管介入治療技術(shù)是治療心血管疾病的重要手段，永久金屬支架雖然可以為冠脈狹窄提供支撐，但其在血管內(nèi)長(zhǎng)期存留可引起血管的慢性損傷，后期可造成血管中層萎縮、動(dòng)脈瘤形成以及反應(yīng)性內(nèi)膜增生，最終導(dǎo)致血管再狹窄。隨著科學(xué)技術(shù)的發(fā)展和實(shí)驗(yàn)的探索，生物可吸收支架正在逐步替代金屬永久支架，成為冠狀動(dòng)脈介入治療發(fā)展的新方向。國(guó)產(chǎn)冠脈支架的發(fā)展經(jīng)歷了模仿、改進(jìn)、創(chuàng)新的漫長(zhǎng)歷程，目前新型的生物可吸收冠狀動(dòng)脈支架已經(jīng)取得了可喜的階段性研究成果。本文綜述了幾種國(guó)產(chǎn)新型生物可吸收支架的發(fā)展情況，歸納其各自的特點(diǎn)和臨床試驗(yàn)結(jié)果，分析了當(dāng)前的問題，并對(duì)未來的發(fā)展做了展望。

[1] 陳灝珠,林果維,王吉耀,等.實(shí)用內(nèi)科學(xué) [M]. 14版.上海:復(fù)旦大學(xué)出版社，2014：1466-1467．

Chen HZ, Lin GW, Wang JY, et al. Practical of internal medicine [M]. 14th ed.Shanghai:Fudan University Press,2014:1466-1467．

[2] 陶波,蔣學(xué)俊,方釗,等.冠狀動(dòng)脈生物可降解支架的研究現(xiàn)狀[J].中國(guó)心血管病研究,2016,14(4):289-292.

Tao B, Jiang XJ, Fang Z, et al.The research of biodegradable coronary artery stents[J].

Chinese Journal of Cardiovascular Research,2016,14(4):289-292.

[3] 唐熠達(dá),陳紀(jì)林.冠狀動(dòng)脈全降解支架的臨床研究進(jìn)展及展望[J].中國(guó)循環(huán)雜志,2016 ,31(5):417-419.

[4] 李家睿,馮邦哲,荊小馬.介入治療界的新星——生物可吸收支架[J].國(guó)際心血管病雜志,2018,45(3):136-138.

[5] 沈靂,葛均波.生物可吸收支架的利弊之爭(zhēng)[J].實(shí)用醫(yī)院臨床雜志,2017, 14(1):1-5.

Shen L, Ge JB. Advantages and disadvantages of bioresorbabel scaffold[J].Clinical Journal of Practical Hospital,2017, 14(1):1-5.

[6] 姜?jiǎng)P迪,王春仁,劉麗,等.基于聚乳酸及其共聚物的生物可吸收支架研究進(jìn)展[J].中國(guó)醫(yī)療器械信息,2019,25（1）：42-45.

Jang KD, Wang CR, Liu L, et al.Current status and future direction of polymeric biodegradable vascular scaffolds[J].China Medical Device Information,2019, ,25（1）： 42-45.

[7] 胡枝敏，凌望，吳美平. 支架植入后抑制平滑肌細(xì)胞過度增殖的研究進(jìn)展[J].中國(guó)醫(yī)藥導(dǎo)報(bào),2020, 17（7）：33-36.

Hu ZM，Ling W，Wu MP. Research progress on inhibiting excessive proliferation of smooth muscle cells after stent implantation[J]. China Medical Herald,2020, 17（7）：33-36.

[8] 郭振,尉海濤,劉全,等.可降解支架與金屬藥物洗脫支架對(duì)冠狀動(dòng)脈狹窄病變PCI術(shù)后安全性的影響[J].中國(guó)老年學(xué)雜志,2018，38(4):780-782.

[9] 高立建,陳紀(jì)林.生物可降解支架的臨床應(yīng)用進(jìn)展[J].中國(guó)循環(huán)雜志, 2017,32(3):215-216.

[10] 楊承志,喬樹賓.生物可降解冠狀動(dòng)脈支架研究進(jìn)展[J].中國(guó)循環(huán)雜志, 2015,30(12):1228-1230.

[11] 楊廣鑫,欒景源.生物可降解金屬血管支架研究進(jìn)展[J].中國(guó)微創(chuàng)外科雜志, 2018,18(8):753-760.

[12] Kerkmeijer LS, Tenekecioglu E, Wykrzykowska JJ．Stent thrombosis in patients with drug-eluting stents and bioresorbable vascular scaffolds: The feared complication[J]. Polish Archives of Internal Medicine-Polskie, 2018,128(1):943-950.

[13] Yamaji K, Ueki Y, Souteyrand G, et al. Mechanisms of very late bioresorbable scaffold thrombosis: The INVEST registry[J]. Journal of the American College of Cardiology, 2017,70(19): 2330-2344.

[14] Chevalier B, Cequier A, Dudek D, et al. Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB Ⅱ Trial )[J]. Eurointervention, 2018,13(13):1561-1564.

[15] Kereiakes DJ, Ellis SG, Metzger C, et al. 3-Year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds the ABSORB Ⅲ trial[J]. Journal of the American College of Cardiology, 2017,70(23):2852-2862.

[16] Gogas BD, King SB, Samady H. Bioresorbable polymeric scaffolds for coronary revascularization: Lessons learnt from ABSORB Ⅲ, ABSORB China, and ABSORB Japan[J]. Global Cardiology Science & Practice, 2015,2015(5):62-69.

[17] 陶波,蔣學(xué)俊,方釗,等.冠狀動(dòng)脈生物可降解支架的研究現(xiàn)狀[J].中國(guó)心血管病研究,2016,14(4):289-292.

Tao B, Jiang XJ, Fang Z, et al. The research of biodegradable coronary artery stents[J]. Chinese Journal of Cardiovascular Research,2016,14(4):289-292.

[18] 宋雷,徐波.中國(guó)生物可吸收支架的研究與展望[J].中國(guó)心血管雜志,2019,24(6): 496-498.

Song L, Xu B. Research status and future perspectives of bioresorbable vascular scaffolds in China[J].Chinese Journal of Cardiovascular Medicine,2019,24(6): 496-498.

[19] 陶凌.NeoVas生物可吸收支架臨床研究結(jié)果報(bào)告[R].西安:曲江國(guó)際會(huì)議中心,2019.

[20] Han YL, Xu B, Fu GS, et al. A randomized trial comparing the NeoVas sirolimus-eluting bioresorbable scaffold and metallic everolimus-eluting stents[J]. JACC Cardiovascular Interventions, 2018,11(3):260-272.

[21] 365醫(yī)學(xué)網(wǎng).TCT 2018｜韓雅玲院士解讀Neovas 可吸收系列研究結(jié)果[EB/OL].（2018-9-26）. http://www.365heart.com/wap1/newwap1/shownews.asp?id=130884.

[22] 齊璐璐,沈靂,吳軼喆.自研生物可吸收支架獲批上市[N].健康報(bào),2020-3-16(2).

[23] 沈靂,葛均波.生物可降解支架的研究與展望[J].中華醫(yī)學(xué)信息導(dǎo)報(bào),2016,31(19): 17.

[24] 國(guó)家藥品監(jiān)督管理局.生物可吸收冠脈雷帕霉素洗脫支架系統(tǒng)產(chǎn)品獲批上市[EB/OL]. （2020-03-05）.https://www.nmpa.gov.cn/directory/web/nmpa/yaowen/ypjgyw/20200305164201151.html.

[25] Wu Y,Shen L,Yin J,et al.Twelve-month angiographic and clinical outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold and a metallic stent in patients with coronary artery disease[J]. International Journal of Cardiology,2019,293:61-66.

[26] 復(fù)旦大學(xué)附屬中山醫(yī)院.十年磨一劍，XINSORB生物可吸收支架獲批上市[EB/OL].（2020-02-12）. http://www.zs-hospital.sh.cn/zsyy/n33/n66/u1ai4875.html.

[27] Song L, Sun ZW, Guan CD, et al. First-in-man study of a thinner-strut sirolimus-eluting bioresorbable scaffold (FUTURE-I): Three-year clinical and imaging outcomes[J]. Catheterization and Cardiovascular Interventions,2020, 95(1):648-657.

[28] Xu B. Firesorb PLLA-based sirolimus-eluting scaffold. transcatheter cardiovasc therapeutics[M]. Washington, DC. USA,2016-10-31.

[29] Xu B, Guan CD, Gao RL. A first-in-man study of the firesorb sirolimus target eluting bioresorbable vascular scaffold in patients with coronary artery disease(FUTURE-Ⅰ):Two-year clinical and imaging outcomes[J]. Chinese Circulation Journal,2018,33(S1):137.

[30] Song L, Sun ZW, Guan CD, et al. First-in-man study of a thinner-strut sirolimus-eluting bioresorbable scaffold (FUTURE-I): Three-year clinical and imaging outcomes[J].Catheterization and Cardiovascular Interventions,2020,95(Suppl 1):648-657.

[31] 高潤(rùn)霖,張澍,王增武,等.新中國(guó)成立七十年來我國(guó)心血管病學(xué)的發(fā)展[J].中國(guó)循環(huán)雜志,2019,34(9): 833-843.

Gao RL, Zhang S, Wang ZW, et al. The development of cardiology in China in 70 years since the founding of the people's republic of China[J].Chinese Circulation Journal,2019,34(9): 833-843.

[32] Zheng JF,Qiu H,Tian Y, et al. Preclinical evaluation of a novel sirolimus-eluting iron bioresorbable coronary scaffold in porcine coronary artery at 6 months[J]. JACC Cardiovascular Interventions, 2019: 12 (3):245-255.

[33] 竇克非.鐵基生物可吸收支架的特點(diǎn)和研究進(jìn)展[R].美國(guó)圣迭戈:圣迭戈會(huì)議中心,2018.

[34] Wu YJ, Sun ZW, Gao LJ, et al. A first-in-man study of the bioheart sirolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease: Six-month clinical and imaging outcomes[J]. Journal of the American College of Cardiology, 2017,70(18) SB:B7.

[35] Guan CD, Gao LJ, Sun ZW, et al. A first-in-man study of the bioheart sirolimus-eluting bioresorbable scaffold in patients with coronary artery disease: One-year clinical and imaging outcomes[J]. Journal of the American College of Cardiology, 2018, 72(13)SB:B158-B159.

[36] Ferdous M, Wu YJ, Guan CD, et al. A first-in-man study of the bioheart sirolimus-eluting bioresorbable scaffold in patients with coronary artery disease: 2-year clinical and imaging outcomes[J]. Journal of the American College of Cardiology, 2019,74(13) :B174.

[37] 沈瑩冉,周永新.生物可降解冠狀動(dòng)脈支架的研究進(jìn)展[J].外科研究與新技術(shù),2014,3(4):267-274.

Shen YR, Zhou YX. Progess of biodegradable coronary stents[J].Surgical Research and New Technique,2014,3(4):267-274.